Ascendis Pharma (ASND) PT Lowered to $165 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $253.00 --0%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Join SI Premium – FREE
JPMorgan analyst Jessica Fye lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $165.00 (from $174.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Ascendis Pharma reports kidney function gains with PTH drug over 5 years
- Super Retail Group Ltd. (SUL:AU) PT Lowered to AUD15 at JPMorgan
- Wesfarmers Ltd. (WES:AU) (WFAFF) PT Lowered to AUD73 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
